PMPRB report reviews new drugs and their potential impact on future drug spending in Canada

Imported from official source

Announcement

Safety Classified by Officially

The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.

November 5, 2024 — Ottawa, ON — Patented Medicine Prices Review Board

The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years. There were over 12,000 drugs in the pipeline in 2023, increasing by an average of 19% per year since 2019.

Oncology represented one third (33%) of medicines in all phases of clinical trials. Treatments for infectious diseases and central nervous system diseases held the second and third largest share of the pipeline.

The Meds Pipeline Monitor focuses on novel medicines undergoing Phase III clinical trials or in pre-registration with the US Food and Drug Administration (FDA) in 2023. It also includes information on other drugs in Phase II that share the same mechanism of action or indication.

This edition of the report also highlights a list of potentially significant new medicines currently under review by Health Canada.

In 2023, over 12,000 new medicines were undergoing clinical trials, compared to 9,000 the year before. The number of drugs in the pipeline is increasing by an average of 19% per year since 2019.

Cancer treatments represented one third (33%) of medicines in all phases of clinical trials. Treatments for infectious diseases and central nervous system diseases held the second and third largest share of the pipeline, at 13% and 12%, respectively.

On average, 20% of medicines in Phase III clinical trials or pre-registration had an early orphan designation approved through the US FDA or the European Medicines Agency (EMA), which is roughly a 33% decrease from previous years. 

This is an extract. The publication continues at the source.

Source: Patented Medicine Prices Review Board. Licence

Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2024/11/pmprb-report-reviews-new-drugs-and-their-potential-impact-on-future-drug-spending-in-canada.html

Officially imported this from Patented Medicine Prices Review Board’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Patented Medicine Prices Review Board — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2024/11/pmprb-report-revi...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.